Improvement of therapy-induced myelodysplastic syndrome by infusion of autologous CD34-positive hematopoietic progenitor cells without chemotherapy.

Recent years have witnessed a dramatic improvement in multiple myeloma (MM) patient care with a current median life expectancy of 6 to 10 years dependent on age. High-dose melphalan followed by aut...